NASDAQ:SGYP - Synergy Pharmaceuticals Stock Price, Price Target & More

$1.75 -0.03 (-1.69 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$1.75
Today's Range$1.74 - $1.79
52-Week Range$1.68 - $4.84
Volume1.83 million shs
Average Volume5.34 million shs
Market Capitalization$441.52 million
P/E Ratio-1.72
Dividend YieldN/A
Beta1.17

About Synergy Pharmaceuticals (NASDAQ:SGYP)

Synergy Pharmaceuticals logoSynergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders. TRULANCE is designed to replicate the function of uroguanylin. Dolcanatide is being evaluated for inflammatory bowel disease (IBD). TRULANCE is approved in the United States under the trademark name TRULANCE, for the treatment of adults with chronic idiopathic constipation (CIC). In addition, it is developing TRULANCE for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Dolcanatide is designed to be an analog of uroguanylin with enhanced resistance to standard digestive breakdown by proteases in the intestine.

Receive SGYP News and Ratings via Email

Sign-up to receive the latest news and ratings for SGYP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SGYP
CUSIP87163930
Phone212-297-0020

Debt

Debt-to-Equity Ratio-21.05%
Current Ratio4.33%
Quick Ratio3.88%

Price-To-Earnings

Trailing P/E Ratio-1.72
Forward P/E Ratio-3.30
P/E GrowthN/A

Sales & Book Value

Annual Sales$16.82 million
Price / Sales25.66
Cash FlowN/A
Price / CashN/A
Book Value($0.02) per share
Price / Book-87.50

Profitability

EPS (Most Recent Fiscal Year)($1.02)
Net Income$-224,330,000.00
Net Margins-1,333.76%
Return on Equity-652.66%
Return on Assets-157.15%

Miscellaneous

Employees313
Outstanding Shares246,660,000

How to Become a New Pot Stock Millionaire

Synergy Pharmaceuticals (NASDAQ:SGYP) Frequently Asked Questions

What is Synergy Pharmaceuticals' stock symbol?

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

How were Synergy Pharmaceuticals' earnings last quarter?

Synergy Pharmaceuticals (NASDAQ:SGYP) posted its quarterly earnings results on Thursday, March, 1st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.03. The biopharmaceutical company earned $9.40 million during the quarter, compared to analyst estimates of $7.12 million. Synergy Pharmaceuticals had a negative net margin of 1,333.76% and a negative return on equity of 652.66%. Synergy Pharmaceuticals's revenue for the quarter was up 840.0% compared to the same quarter last year. View Synergy Pharmaceuticals' Earnings History.

What price target have analysts set for SGYP?

8 analysts have issued twelve-month target prices for Synergy Pharmaceuticals' shares. Their forecasts range from $2.50 to $15.00. On average, they anticipate Synergy Pharmaceuticals' stock price to reach $8.8125 in the next year. View Analyst Ratings for Synergy Pharmaceuticals.

What are Wall Street analysts saying about Synergy Pharmaceuticals stock?

Here are some recent quotes from research analysts about Synergy Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York. " (3/1/2018)
  • 2. Cantor Fitzgerald analysts commented, "As we predicted in a report published last week, SGYP disclosed that the cash balance at the end of January exceeded the $128 million level required to access $100 million from the CRG Term Loan Agreement." (2/1/2018)

Are investors shorting Synergy Pharmaceuticals?

Synergy Pharmaceuticals saw a increase in short interest in March. As of March 29th, there was short interest totalling 60,391,166 shares, an increase of 2.4% from the March 15th total of 61,879,187 shares. Based on an average trading volume of 4,169,422 shares, the short-interest ratio is presently 14.5 days. Approximately 24.5% of the shares of the company are sold short.

Who are some of Synergy Pharmaceuticals' key competitors?

Who are Synergy Pharmaceuticals' key executives?

Synergy Pharmaceuticals' management team includes the folowing people:
  • Gary S. Jacob Ph.D., Executive Chairman of the Board (Age 70)
  • Troy Hamilton, Chief Executive Officer, Director (Age 45)
  • Gary G. Gemignani, Chief Financial Officer, Executive Vice President (Age 52)
  • Marino Garcia, Executive Vice President, Chief Strategy Officer (Age 50)
  • Patrick H. Griffin M.D., Executive Vice President, Chief Medical Officer (Age 61)
  • Melvin K. Spigelman M.D., Lead Independent Director (Age 68)
  • Thomas H. Adams Jr. Ph.D., Independent Director (Age 74)
  • John P. Brancaccio CPA, Independent Director (Age 69)
  • Timothy S. Callahan, Independent Director (Age 46)
  • Richard J. Daly, Independent Director (Age 56)

Has Synergy Pharmaceuticals been receiving favorable news coverage?

News articles about SGYP stock have been trending somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Synergy Pharmaceuticals earned a news sentiment score of 0.10 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 45.31 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Synergy Pharmaceuticals?

Shares of SGYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Synergy Pharmaceuticals' stock price today?

One share of SGYP stock can currently be purchased for approximately $1.75.

How big of a company is Synergy Pharmaceuticals?

Synergy Pharmaceuticals has a market capitalization of $441.52 million and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Synergy Pharmaceuticals employs 313 workers across the globe.

How can I contact Synergy Pharmaceuticals?

Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]


MarketBeat Community Rating for Synergy Pharmaceuticals (SGYP)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  526 (Vote Outperform)
Underperform Votes:  218 (Vote Underperform)
Total Votes:  744
MarketBeat's community ratings are surveys of what our community members think about Synergy Pharmaceuticals and other stocks. Vote "Outperform" if you believe SGYP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGYP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Synergy Pharmaceuticals (NASDAQ:SGYP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Synergy Pharmaceuticals in the last 12 months. Their average twelve-month price target is $8.8125, suggesting that the stock has a possible upside of 403.57%. The high price target for SGYP is $15.00 and the low price target for SGYP is $2.50. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.632.632.672.80
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.8125$8.8125$8.9444$8.90
Price Target Upside: 403.57% upside361.39% upside310.30% upside193.73% upside

Synergy Pharmaceuticals (NASDAQ:SGYP) Consensus Price Target History

Price Target History for Synergy Pharmaceuticals (NASDAQ:SGYP)

Synergy Pharmaceuticals (NASDAQ:SGYP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2018OppenheimerReiterated RatingHoldLowView Rating Details
3/5/2018HC WainwrightSet Price TargetBuy$7.00MediumView Rating Details
2/1/2018Cantor FitzgeraldReiterated RatingBuyHighView Rating Details
1/5/2018CIBCReiterated RatingOutperform -> Market PerformHighView Rating Details
1/5/2018CitigroupDowngradeMarket PerformHighView Rating Details
11/14/2017BTIG ResearchReiterated RatingBuy$7.00N/AView Rating Details
11/12/2017Canaccord GenuitySet Price TargetBuy$13.00N/AView Rating Details
8/10/2017Rodman & RenshawLower Price TargetBuy -> Buy$18.00 -> $15.00HighView Rating Details
3/2/2017GuggenheimReiterated RatingOutperform$10.00N/AView Rating Details
12/15/2016Roth CapitalReiterated RatingBuy$6.50N/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Synergy Pharmaceuticals (NASDAQ:SGYP) Earnings History and Estimates Chart

Earnings by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Synergy Pharmaceuticals (NASDAQ:SGYP) Earnings Estimates

2018 EPS Consensus Estimate: ($0.52)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.15)($0.15)($0.15)
Q2 20181($0.14)($0.14)($0.14)
Q3 20181($0.12)($0.12)($0.12)
Q4 20181($0.11)($0.11)($0.11)

Synergy Pharmaceuticals (NASDAQ SGYP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2018Q4 2017($0.19)($0.16)$7.12 million$9.40 millionViewListenView Earnings Details
11/9/2017Q3 2017($0.28)($0.22)$4.53 million$5.01 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.25)($0.33)$1.98 million$2.31 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.2260)($0.30)$0.10 million$0.10 millionViewN/AView Earnings Details
3/1/2017Q4 2016($0.20)($0.31)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.22)($0.22)ViewN/AView Earnings Details
8/8/2016Q216($0.20)($0.23)ViewN/AView Earnings Details
5/10/2016Q1($0.23)($0.51)ViewN/AView Earnings Details
2/25/2016Q4 2015($0.25)($0.27)ViewN/AView Earnings Details
11/9/2015Q315($0.28)($0.23)ViewN/AView Earnings Details
8/10/2015Q215($0.28)($0.34)$102.00 millionViewN/AView Earnings Details
5/11/2015Q115($0.33)($0.28)ViewN/AView Earnings Details
3/16/2015($0.28)($0.32)ViewN/AView Earnings Details
11/10/2014($0.28)($0.24)ViewN/AView Earnings Details
8/11/2014($0.23)($0.28)ViewN/AView Earnings Details
5/13/2014Q114($0.23)($0.18)ViewN/AView Earnings Details
3/17/2014Q4 13($0.20)($0.22)ViewN/AView Earnings Details
11/12/2013Q3($0.17)($0.15)ViewN/AView Earnings Details
8/9/2013Q2 2013($0.23)($0.13)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.17)($0.24)ViewN/AView Earnings Details
3/18/2013Q4 2012($0.15)($0.17)ViewN/AView Earnings Details
11/13/2012Q312($0.01)($0.15)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.13)ViewN/AView Earnings Details
3/15/2012Q4 2011($0.12)($0.12)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Synergy Pharmaceuticals (NASDAQ:SGYP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Synergy Pharmaceuticals (NASDAQ SGYP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.80%
Institutional Ownership Percentage: 53.08%
Insider Trading History for Synergy Pharmaceuticals (NASDAQ:SGYP)
Institutional Ownership by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Synergy Pharmaceuticals (NASDAQ SGYP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/10/2017Paulson & Co. Inc.Major ShareholderSell8,750,000$2.82$24,675,000.00View SEC Filing  
8/7/2017Paulson & Co. Inc.Major ShareholderSell26,287$3.77$99,101.99View SEC Filing  
5/26/2017Gary S JacobCEOBuy5,680$3.52$19,993.60402,679View SEC Filing  
5/26/2017John P BrancaccioDirectorBuy6,500$3.59$23,335.0030,444View SEC Filing  
11/4/2016Paulson & Co. Inc.Major ShareholderSell140,000$4.24$593,600.00View SEC Filing  
9/28/2016Paulson & Co. Inc.Major ShareholderSell54,300$5.69$308,967.00View SEC Filing  
9/19/2016John P BrancaccioDirectorSell2,518$5.76$14,503.6821,883View SEC Filing  
9/19/2016Paulson & Co. Inc.Major ShareholderSell3,473,713$5.61$19,487,529.93View SEC Filing  
9/14/2015Bernard DenoyerSVPSell10,000$7.50$75,000.00View SEC Filing  
9/11/2015Alan JoslynDirectorSell13,754$7.22$99,303.88View SEC Filing  
6/3/2014John P BrancaccioDirectorBuy3,500$4.12$14,420.00View SEC Filing  
5/27/2014Gary S JacobCEOBuy4,000$4.18$16,720.00View SEC Filing  
5/23/2014Bernard DenoyerSVPBuy2,500$3.89$9,725.00View SEC Filing  
5/23/2014Kunwar ShailubhaiInsiderBuy3,000$3.89$11,670.00View SEC Filing  
10/29/2013Gabriel CerroneDirectorBuy12,000$4.09$49,080.00View SEC Filing  
6/21/2013Bernard DenoyerSVPBuy7,500$4.78$35,850.00View SEC Filing  
6/14/2013Gabriel CerroneChairmanBuy8,000$4.42$35,360.00View SEC Filing  
4/24/2013Gabriel CerroneChairmanBuy5,500$4.66$25,630.00View SEC Filing  
2/5/2013Gabriel CerroneChairmanBuy5,000$6.15$30,750.00View SEC Filing  
2/4/2013Gabriel CerroneChairmanBuy13,090$6.04$79,063.60View SEC Filing  
1/30/2013Gabriel CerroneChairmanBuy26,000$5.98$155,480.00View SEC Filing  
11/14/2012Gabriel CerroneChairmanBuy87,820$3.61$317,030.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Synergy Pharmaceuticals (NASDAQ SGYP) News Headlines

Source:
DateHeadline
Synergy Pharmaceuticals (SGYP) Stock Rating Reaffirmed by BTIG ResearchSynergy Pharmaceuticals (SGYP) Stock Rating Reaffirmed by BTIG Research
www.americanbankingnews.com - April 20 at 4:17 PM
Options Traders Expect Huge Moves in Synergy Pharmaceuticals (SGYP) StockOptions Traders Expect Huge Moves in Synergy Pharmaceuticals (SGYP) Stock
finance.yahoo.com - April 18 at 9:35 AM
Synergy Pharmaceuticals (SGYP) Expected to Earn Q1 2018 Earnings of ($0.15) Per ShareSynergy Pharmaceuticals (SGYP) Expected to Earn Q1 2018 Earnings of ($0.15) Per Share
www.americanbankingnews.com - April 18 at 7:42 AM
-$0.16 EPS Expected for Synergy Pharmaceuticals (SGYP) This Quarter-$0.16 EPS Expected for Synergy Pharmaceuticals (SGYP) This Quarter
www.americanbankingnews.com - April 16 at 9:21 AM
Synergy Pharmaceuticals (SGYP) Given a $13.00 Price Target by Canaccord Genuity AnalystsSynergy Pharmaceuticals (SGYP) Given a $13.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - April 15 at 8:37 AM
Synergy Pharmaceuticals (SGYP) Receives Average Recommendation of "Hold" from BrokeragesSynergy Pharmaceuticals (SGYP) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 11 at 6:19 PM
Synergy Pharmaceuticals (SGYP) Earns Buy Rating from Cantor FitzgeraldSynergy Pharmaceuticals (SGYP) Earns Buy Rating from Cantor Fitzgerald
www.americanbankingnews.com - April 11 at 6:13 PM
Synergy Pharmaceuticals (SGYP) Given a $9.00 Price Target by Oppenheimer AnalystsSynergy Pharmaceuticals (SGYP) Given a $9.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - April 11 at 1:27 PM
HC Wainwright Analysts Give Synergy Pharmaceuticals (SGYP) a $15.00 Price TargetHC Wainwright Analysts Give Synergy Pharmaceuticals (SGYP) a $15.00 Price Target
www.americanbankingnews.com - April 11 at 12:11 AM
SGYP DEADLINE TODAY: The Law Offices of Vincent Wong Reminds Investors of Class Actions Involving Synergy Pharmaceuticals Inc. and a Lead Plaintiff Deadline of April 10, 2018SGYP DEADLINE TODAY: The Law Offices of Vincent Wong Reminds Investors of Class Actions Involving Synergy Pharmaceuticals Inc. and a Lead Plaintiff Deadline of April 10, 2018
finance.yahoo.com - April 10 at 4:40 PM
FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Synergy Pharmaceuticals Inc. (SGYP) & Lead Plaintiff Deadline: April 10, 2018FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Synergy Pharmaceuticals Inc. (SGYP) & Lead Plaintiff Deadline: April 10, 2018
finance.yahoo.com - April 10 at 4:40 PM
Glancy Prongay & Murray LLP Reminds Investors of the April 10, 2018 Deadline in the Class Action Lawsuit Against Synergy Pharmaceuticals Inc. (SGYP)Glancy Prongay & Murray LLP Reminds Investors of the April 10, 2018 Deadline in the Class Action Lawsuit Against Synergy Pharmaceuticals Inc. (SGYP)
finance.yahoo.com - April 10 at 4:40 PM
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The FirmDEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm
finance.yahoo.com - April 10 at 4:40 PM
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Synergy Pharmaceuticals ...Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Synergy Pharmaceuticals ...
www.businesswire.com - April 10 at 9:29 AM
EQUITY NOTICE: Rosen Law Firm Reminds Synergy Pharmaceuticals Inc. Investors of Important April 10, 2018 ...EQUITY NOTICE: Rosen Law Firm Reminds Synergy Pharmaceuticals Inc. Investors of Important April 10, 2018 ...
www.businesswire.com - April 10 at 9:29 AM
FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Reminds Investors With Losses In Excess of $50,000 To Contact The FirmFINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Reminds Investors With Losses In Excess of $50,000 To Contact The Firm
finance.yahoo.com - April 9 at 4:43 PM
DEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Reminds Investors With Losses In Excess of $100,000 To Contact The FirmDEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Reminds Investors With Losses In Excess of $100,000 To Contact The Firm
finance.yahoo.com - April 7 at 4:57 PM
Synergy Pharmaceuticals (SGYP) Given a $6.00 Price Target by Oppenheimer AnalystsSynergy Pharmaceuticals (SGYP) Given a $6.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - April 7 at 12:36 PM
Synergy Pharmaceuticals (SGYP) Given a $8.00 Price Target at HC WainwrightSynergy Pharmaceuticals (SGYP) Given a $8.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 6 at 3:32 PM
Synergy Pharmaceuticals Inc. Reminder: Important April 10, 2018 Lead Plaintiff Deadline in Class Action– SGYPSynergy Pharmaceuticals Inc. Reminder: Important April 10, 2018 Lead Plaintiff Deadline in Class Action– SGYP
finance.yahoo.com - April 6 at 9:30 AM
Quotidian Technical Highlights on Selected Healthcare Stocks -- GlaxoSmithKline, Synergy Pharma, Teva Pharma, and PerrigoQuotidian Technical Highlights on Selected Healthcare Stocks -- GlaxoSmithKline, Synergy Pharma, Teva Pharma, and Perrigo
www.bizjournals.com - April 5 at 4:40 PM
5-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Reminds Investors With Losses In Excess of $100,000 To Contact The Firm5-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Reminds Investors With Losses In Excess of $100,000 To Contact The Firm
finance.yahoo.com - April 5 at 4:40 PM
Kessler Topaz Meltzer & Check, LLP: Final Deadline Reminder For Synergy Pharmaceuticals Inc. Shareholders - SGYPKessler Topaz Meltzer & Check, LLP: Final Deadline Reminder For Synergy Pharmaceuticals Inc. Shareholders - SGYP
finance.yahoo.com - April 5 at 4:40 PM
SGYP UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of Class Actions Involving Synergy Pharmaceuticals Inc. and a Lead Plaintiff Deadline of April 10, 2018SGYP UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of Class Actions Involving Synergy Pharmaceuticals Inc. and a Lead Plaintiff Deadline of April 10, 2018
finance.yahoo.com - April 5 at 4:40 PM
Quotidian Technical Highlights on Selected Healthcare Stocks -- GlaxoSmithKline, Synergy Pharma, Teva Pharma, and ...Quotidian Technical Highlights on Selected Healthcare Stocks -- GlaxoSmithKline, Synergy Pharma, Teva Pharma, and ...
www.prnewswire.com - April 5 at 9:17 AM
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Synergy Pharmaceuticals, Inc. (SGYP) and Encourages Investors to Contact the Firm Before April 10thDEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Synergy Pharmaceuticals, Inc. (SGYP) and Encourages Investors to Contact the Firm Before April 10th
finance.yahoo.com - April 4 at 4:50 PM
7-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Reminds Investors With Losses In Excess of $100,000 To Contact The Firm7-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Reminds Investors With Losses In Excess of $100,000 To Contact The Firm
finance.yahoo.com - April 3 at 4:40 PM
The Klein Law Firm Reminds Investors of Commencement of Class Actions on Behalf of Synergy Pharmaceuticals Inc. Shareholders and a Lead Plaintiff Deadline of April 10, 2018The Klein Law Firm Reminds Investors of Commencement of Class Actions on Behalf of Synergy Pharmaceuticals Inc. Shareholders and a Lead Plaintiff Deadline of April 10, 2018
finance.yahoo.com - April 3 at 4:40 PM
FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Synergy Pharmaceuticals Inc. to Contact the FirmFINAL DEADLINE ALERT: Brower Piven Reminds Shareholders of Approaching Deadline in Class Action Lawsuit and Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Synergy Pharmaceuticals Inc. to Contact the Firm
finance.yahoo.com - April 1 at 9:19 AM
Synergy Pharmaceuticals (SGYP) Expected to Post Quarterly Sales of $12.20 MillionSynergy Pharmaceuticals (SGYP) Expected to Post Quarterly Sales of $12.20 Million
www.americanbankingnews.com - April 1 at 4:02 AM
3 Favorite Biotech Stocks for the Second Quarter3 Favorite Biotech Stocks for the Second Quarter
finance.yahoo.com - March 31 at 4:39 PM
IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Reminds Investors With Losses In Excess of $100,000 To Contact The FirmIMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Reminds Investors With Losses In Excess of $100,000 To Contact The Firm
finance.yahoo.com - March 30 at 4:46 PM
Synergy Pharmaceuticals (SGYP) Given a $7.00 Price Target by HC Wainwright AnalystsSynergy Pharmaceuticals (SGYP) Given a $7.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 30 at 1:14 PM
Zacks: Analysts Expect Synergy Pharmaceuticals (SGYP) to Post -$0.16 Earnings Per ShareZacks: Analysts Expect Synergy Pharmaceuticals (SGYP) to Post -$0.16 Earnings Per Share
www.americanbankingnews.com - March 30 at 11:23 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Synergy Pharmaceuticals Inc. of Class Actions and a Lead Plaintiff Deadline of April 10, 2018 - SGYPSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Synergy Pharmaceuticals Inc. of Class Actions and a Lead Plaintiff Deadline of April 10, 2018 - SGYP
finance.yahoo.com - March 29 at 4:40 PM
APRIL 10 DEADLINE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Reminds Investors With Losses In Excess of $100,000 To Contact The FirmAPRIL 10 DEADLINE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Reminds Investors With Losses In Excess of $100,000 To Contact The Firm
finance.yahoo.com - March 29 at 9:32 AM
The Klein Law Firm Reminds Investors of the Commencement of Class Actions on Behalf of Synergy Pharmaceuticals Inc. Shareholders and a Lead Plaintiff Deadline of April 10, 2018The Klein Law Firm Reminds Investors of the Commencement of Class Actions on Behalf of Synergy Pharmaceuticals Inc. Shareholders and a Lead Plaintiff Deadline of April 10, 2018
finance.yahoo.com - March 28 at 4:38 PM
Synergy Pharmaceuticals (SGYP) Lifted to Hold at BidaskClubSynergy Pharmaceuticals (SGYP) Lifted to Hold at BidaskClub
www.americanbankingnews.com - March 26 at 10:58 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Synergy Pharmaceuticals Inc. of Commencement of Class Actions and a Lead Plaintiff Deadline of April 10, 2018 - SGYPSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Synergy Pharmaceuticals Inc. of Commencement of Class Actions and a Lead Plaintiff Deadline of April 10, 2018 - SGYP
finance.yahoo.com - March 26 at 4:49 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Synergy Pharmaceuticals Inc. (SGYP) & Lead Plaintiff Deadline: April 10, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Synergy Pharmaceuticals Inc. (SGYP) & Lead Plaintiff Deadline: April 10, 2018
finance.yahoo.com - March 26 at 4:49 PM
Synergy Pharmaceuticals Inc (NASDAQ:SGYP): Is Breakeven Near?Synergy Pharmaceuticals Inc (NASDAQ:SGYP): Is Breakeven Near?
finance.yahoo.com - March 23 at 6:15 PM
Synergy Pharmaceuticals (SGYP) Receives "Hold" Rating from OppenheimerSynergy Pharmaceuticals (SGYP) Receives "Hold" Rating from Oppenheimer
www.americanbankingnews.com - March 23 at 6:06 PM
SGYP INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Class Actions Involving Synergy Pharmaceuticals Inc. and a Lead Plaintiff Deadline of April 10, 2018SGYP INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Class Actions Involving Synergy Pharmaceuticals Inc. and a Lead Plaintiff Deadline of April 10, 2018
finance.yahoo.com - March 22 at 4:53 PM
Kessler Topaz Meltzer & Check, LLP - Deadline Reminder for Synergy Pharmaceuticals Inc. Shareholders – SGYPKessler Topaz Meltzer & Check, LLP - Deadline Reminder for Synergy Pharmaceuticals Inc. Shareholders – SGYP
feeds.benzinga.com - March 22 at 8:37 AM
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Synergy Pharmaceuticals Inc. of Class Actions and a Lead Plaintiff Deadline of April 10, 2018 - SGYPEQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Synergy Pharmaceuticals Inc. of Class Actions and a Lead Plaintiff Deadline of April 10, 2018 - SGYP
finance.yahoo.com - March 21 at 4:58 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Synergy Pharmaceuticals Inc. (SGYP) and Lead Plaintiff Deadline: April 10, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Synergy Pharmaceuticals Inc. (SGYP) and Lead Plaintiff Deadline: April 10, 2018
finance.yahoo.com - March 21 at 4:58 PM
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Synergy Pharmaceuticals Inc. Shareholders and a Lead Plaintiff Deadline of April 10, 2018The Klein Law Firm Reminds Investors of Class Actions on Behalf of Synergy Pharmaceuticals Inc. Shareholders and a Lead Plaintiff Deadline of April 10, 2018
finance.yahoo.com - March 20 at 4:49 PM
DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Encourages Investors With Losses To Contact The FirmDEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. And Encourages Investors With Losses To Contact The Firm
finance.yahoo.com - March 20 at 9:14 AM
Synergy Pharmaceuticals Inc (SGYP) Receives Average Rating of "Hold" from BrokeragesSynergy Pharmaceuticals Inc (SGYP) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 17 at 5:30 PM
SYNERGY PHARMACEUTICALS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Synergy Pharmaceuticals, Inc.SYNERGY PHARMACEUTICALS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Synergy Pharmaceuticals, Inc.
finance.yahoo.com - March 16 at 4:52 PM

SEC Filings

Synergy Pharmaceuticals (NASDAQ:SGYP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Synergy Pharmaceuticals (NASDAQ:SGYP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Synergy Pharmaceuticals (NASDAQ SGYP) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.